In the world of biomedical innovation, few stories embody the spirit of perseverance, intuition, and collaboration quite like that of Dr. Kannan Rangaramanujam, the Arnall Patz Distinguished Professor of Ophthalmology and Co-Director of the Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins School of Medicine.
Stay updated on our latest research highlights, publications, awards, and lab activities as we advance for clinical impact ...
Hopkins researchers develop COVID-19 nanomedicine, promising Phase 2 results
Johns Hopkins researchers developed OP-101, a nanomedicine that targets inflammation and shows promise against severe COVID-19.
Ashvattha reports positive 40-week Phase 2 results for migaldendranib.
Announced Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Dr. Parikh – T.Boone Pickens Rising Professor
Wilmer Eye Institute Names Dr. Kunal Parikh Inaugural Boone Pickens Rising Professor
Dedication of the Arnall Patz Distinguished Professorship
Dr. Kannan Rangaramanujam, Ph.D., was named the Arnall Patz Distinguished Professor and highlighted how nanotechnology-based drug delivery targeting inflammation can impact AMD and other diseases.
